# US 2008/0306027 A1 · Fluoroalkoxycombretastatin Derivatives, Method For Producing the Same and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306027 A1
- Document ID: US20080306027A1
- Status: Published application
- Kind: A1
- Application number: 12/088,984
- Filed: 2006-11-22
- Published: 2008-12-11
- Earliest claimed: 2006-06-06
- Assignees: Zhejiang Dade Pharmaceutical Group Co., Ltd.
- Inventors: Weiping Shen; Jianping Wang; Jianguo Wang; Feng Qian; Fei Wang; Hongmei Jin
- Web page: https://patentgrep.com/patent/US20080306027A1

## CPC

- C07C 217/84: the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/22: for herpes viruses
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 43/23: containing hydroxy or O-metal groups
- C07C 237/04: the carbon skeleton being acyclic and saturated
- C07F 9/12: with hydroxyaryl compounds
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Combretastatin derivatives of formula (I), preparation and use thereof are disclosed, wherein: Rf is alkyl with 1-8 carbon atoms and 1-17 fluorine atoms, R is amino, substituted amino, hydroxyl, nitro, halo, alkyloxy, phosphate or amino acid side chain. Said derivatives have a capability to inhibit the polymerization of microtubules and are useful in treatment against tumor and neovascularization.

## Claims

### Claim 1

A compound of formula (I)
Wherein Rf is an alkyl group having 1 to 8 carbon atoms in which 1 to 17 hydrogen atoms being substituted by 1 to 17 fluorine atoms;
R is amino, substituted amino, hydroxyl, nitro, halogen, alkoxy, phosphate or side chain of an amino acid and its pharmaceutically acceptable salts.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Rf and R are selected from the following groups:
(a) Rf is fluoromethyl, R is hydroxyl;
(b) Rf is fluoromethyl, R is amino or substituted amino;
(c) Rf is fluoromethyl, R is disodium phosphate or ammonium phosphate or internal salt of phosphorylcholine;
or (d) Rf is fluoromethyl, R is —NH(COCHR′NH)m—H, R′ is hydrogen, side chain of a nature amino acid, phenyl, m is an integer of 1 to 3.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Rf and R are selected from the following groups:
(a) Rf is fluoroethyl, R is hydroxyl;
(b) Rf is fluoroethyl, R is amino or substituted amino;
(c) Rf is fluoroethyl, R is disodium phosphate or ammonium phosphate or internal salt of phosphorylcholine;
or (d) Rf is fluoroethyl, R is —NH(COCHR′NH)m—H, R′ is hydrogen, side chain of a nature amino acid, phenyl, m is an integer of 1 to 3.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Rf and R are selected from the following groups:
(a) Rf=—CH2F, —CHF2, —CF3, —CH2CF3, —CH2CHF2 or —CF2CF3, R≡—OH or —OPO3Na2;
or (b) RfCH2F, —CHF2, —CF3, —CH2CF3, —CH2CHF2 or —CF2CF3, R≡—NH2 or —NHCOCH(NH2)CH2OH.

### Claim 5 (depends on 1)

A method for preparing the compound in accordance with claim 1, characterized in comprising the steps of:
(1) Under phase-transfer catalyst conditions, 4-hydroxy-3-methoxybenzaldehyde III being fluoroalkoxylated with fluorine-containing reagent to synthesize 4-fluoroalkoxy-3-methoxybenzaldehyde represented by formula V;
(2) Using lithium diphenylphosphine, 4-fluoroalkoxy-3-methoxybenzaldehyde being demethylated to synthesize 4-fluoroalkoxy-3-hydroxybenzaldehyde represented by formula VI;
(3) The hydroxyl of 4-fluoroalkoxy-3-hydroxybenzaldehyde VI being protected, and then was reacted with 3,4,5-trimethoxybenzyltriphenylphosphonium ylid via Wittig reaction, and the resulted compound being released from protection to obtain the compound of formula I in accordance with claim 1.

### Claim 6 (depends on 1)

A method for preparing the compound in accordance with claim 1, characterized in comprising the steps of:
(a) Under phase-transfer catalyst conditions, 4-hydroxybenzaldehyde IV being fluoroalkylated with fluorine-containing reagent to synthesize 4-fluoroalkoxybenzaldehyde represented by formula VII;
(b) 4-Fluoroalkoxybenzaldehyde VII being nitrated in 3 position of phenyl ring with nitric acid and acetic anhydride to synthesize 4-fluoroalkoxy-3-nitrobenzaldehyde, which is represented by formula VIII;
(c) 4-fluoroalkoxy-3-nitrobenzaldehyde VIII being reacted with 3,4,5-trimethoxybenzyltriphenylphosphine ylid via Wittig reaction to obtain the compounds of formula I in accordance with claim 1.

### Claim 7 (depends on 5)

The method of claim 5, wherein the fluorine-containing reagent is fluorohalomethane or fluoroalkyl sulphonate.

### Claim 8 (depends on 1)

A pharmaceutical composition characterized in comprising the compound in accordance with claim 1 of therapeutical effective dosage and pharmaceutically acceptable carrier.

### Claim 9 (depends on 1)

Use of the compound in accordance with claim 1 for the manufacturing of a tubulin-binding inhibitor.

### Claim 10 (depends on 1)

Use of the compound in accordance with claim 1 for the manufacturing of a medicament for the treatment of the diseases caused by abnormal angiogenesis.

### Claim 11 (depends on 6)

The method of claim 6, wherein the fluorine-containing reagent is fluorohalomethane or fluoroalkyl sulphonate.
